Tumor-infiltrating lymphocyte therapy and the mucosal melanoma treatment landscape

Jennifer Thomas; Max Julve; James Larkin; Andrew Furness

doi:10.1002/cac2.70069

Cancer Communications ›› 2025, Vol. 45 ›› Issue (11) :1579 -1582. DOI: 10.1002/cac2.70069

RESEARCH HIGHLIGHTS

Tumor-infiltrating lymphocyte therapy and the mucosal melanoma treatment landscape

Author information +

History +

PDF

Cite this article

Download citation ▾

Jennifer Thomas, Max Julve, James Larkin, Andrew Furness. Tumor-infiltrating lymphocyte therapy and the mucosal melanoma treatment landscape. Cancer Communications, 2025, 45(11): 1579-1582 DOI:10.1002/cac2.70069

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun. 2019;10(1):3163.

[2]	D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, et al. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. J Clin Oncol. 2017;35(2):226–35.

[3]	Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327–34.

[4]	Larkin J, Marais R, Porta N, Gonzalez de Castro D, Parsons L, Messiou C, et al. Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial. Cell Rep Med. 2024;5(3):101435.

[5]

Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10(12):e005755.

[6]	Julve M, Lythgoe MP, Larkin J, Furness AJS. Lifileucel: the first cellular therapy approved for solid tumours. Trends Cancer. 2024;10(6):475–7.

[7]	Kluger H, Grigoleit GU, Thomas S, Domingo-Musibay E, Chesney JA, Sanmamed MF, et al. Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Commun (Lond). 2025 July 22.

[8]	Vos JL, Traets JJ, Qiao X, Seignette IM, Peters D, Wouters MW, et al. Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma. JCI Insight. 2024;9(21):e179982.

[9]	Chen YP, Zhang WW, Qiu YT, Ke LF, Chen H, Chen G. PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics. Histopathology. 2023;82(2):285–95.

[10]	Wermke M, Araujo DM, Chatterjee M, Tsimberidou AM, Holderried TAW, Jazaeri AA, et al. Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial. Nat Med. 2025;31(7):2365-74.

[11]	Shi C, Ju H, Zhou R, Xu S, Wu Y, Gu Z, et al. The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification. BMC Med. 2024;22(1):215.